Bank Of America Corp Verona Pharma PLC Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Verona Pharma PLC stock. As of the latest transaction made, Bank Of America Corp holds 611,018 shares of VRNA stock, worth $18.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

611,018

Previous 128,399 375.87%

Holding current value

$18.2 Million

Previous $2.07 Million 327.85%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $5.54 Million - $8.21 Million	482,619 Added 375.87%	611,018 $8.84 Million
Q1 2024 May 15, 2024	BUY	$15.3 - $20.24 $679,518 - $898,919	44,413 Added 52.88%	128,399 $2.07 Million
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $253,832 - $435,171	21,259 Added 33.89%	83,986 $1.67 Million
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $288,781 - $348,591	-14,878 Reduced 19.17%	62,727 $1.33 Million
Q1 2023 May 12, 2023	BUY	$18.06 - $25.27 $662,910 - $927,560	36,706 Added 89.75%	77,605 $1.56 Million
Q4 2022 Feb 10, 2023	BUY	$9.84 - $26.13 $388,866 - $1.03 Million	39,519 Added 2863.7%	40,899 $1.07 Million
Q3 2022 Nov 14, 2022	SELL	$4.14 - $13.59 $1,229 - $4,036	-297 Reduced 17.71%	1,380 $14,000
Q2 2022 Aug 12, 2022	BUY	$3.55 - $5.06 $3,841 - $5,474	1,082 Added 181.85%	1,677 $7,000
Q1 2022 May 16, 2022	SELL	$4.82 - $6.98 $1,913 - $2,771	-397 Reduced 40.02%	595 $3,000
Q4 2021 Feb 08, 2022	SELL	$3.91 - $7.08 $39,404 - $71,352	-10,078 Reduced 91.04%	992 $7,000
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $40,812 - $48,990	7,715 Added 229.96%	11,070 $60,000
Q2 2021 Sep 13, 2021	BUY	$5.72 - $9.09 $19,190 - $30,496	3,355 New	3,355 $22,000

Others Institutions Holding VRNA

# of Institutions

137

Shares Held

66.7M

Call Options Held

495K

Put Options Held

486K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $1.82B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Verona Pharma PLC Transaction History